Literature DB >> 9293954

Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy.

L Sieverding1, W I Jung, J Breuer, S Widmaier, A Staubert, F van Erckelens, O Schmidt, M Bunse, T Hoess, O Lutz, G J Dietze, J Apitz.   

Abstract

Disturbed myocardial energy metabolism may occur in patients with primary hypertrophic cardiomyopathy (HCM). A noninvasive way to gain insight into cardiac energy metabolism is provided by in vivo 31P nuclear magnetic resonance (NMR) spectroscopy. 31P NMR spectroscopy with proton decoupling was performed in 13 patients aged 13-36 years with HCM on a 1.5 T Magnetom with a double resonant surface coil. A 2D chemical shift imaging (CSI) sequence in combination with slice selective excitation was used to acquire spectra of the anteroseptal region of the left ventricle (volume element: 38 mL). The chemical shifts of the phosphorus metabolites, intracellular pHi, and coupling constants J(alphabeta) and J(gammabeta) were calculated. Peak areas of 2,3-diphosphoglycerate (DPG), Pi, and adenosine triphosphate (ATP) were determined and corrected for blood contamination, saturation, and differences in nuclear Overhauser enhancements (NOE). The maximum thickness of the interventricular septum (IVSmax) was determined from tomographic long-axis images and expressed as number of standard deviations above the mean of the normal population (Z score). The patients were then divided into 2 groups: 6 patients with moderate HCM (HCMm, Z score < or = 5) and 7 patients with severe HCM (HCMs, Z score > 5). No differences between both groups and a control group of healthy volunteers (n = 16) were found with respect to phosphocreatine (PCr)/gamma-ATP ratio, pHi, or the coupling constants. Only the PCr/Pi ratio differed significantly from the control group (HCM(all), alpha < 0.05, HCMs, alpha < 0.02, 2-sided U test). The decrease of the PCr/Pi ratio in patients with HCM is probably caused by ischemically decreased oxygen supply in the severely hypertrophied myocardium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293954     DOI: 10.1016/s0002-9149(97)00456-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Can an energy-deficient heart grow bigger and stronger?

Authors:  Robert Roberts; Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

Review 2.  Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.

Authors:  Valentin Fuster; Sarina van der Zee; Marc A Miller
Journal:  J Cardiovasc Transl Res       Date:  2009-10-16       Impact factor: 4.132

3.  Increased cardiac Pi/PCr in the diabetic heart observed using phosphorus magnetic resonance spectroscopy at 7T.

Authors:  Ladislav Valkovič; Andrew Apps; Jane Ellis; Stefan Neubauer; Damian J Tyler; Albrecht Ingo Schmid; Oliver J Rider; Christopher T Rodgers
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

4.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

5.  Measuring inorganic phosphate and intracellular pH in the healthy and hypertrophic cardiomyopathy hearts by in vivo 7T 31P-cardiovascular magnetic resonance spectroscopy.

Authors:  Ladislav Valkovič; William T Clarke; Albrecht I Schmid; Betty Raman; Jane Ellis; Hugh Watkins; Matthew D Robson; Stefan Neubauer; Christopher T Rodgers
Journal:  J Cardiovasc Magn Reson       Date:  2019-03-14       Impact factor: 5.364

Review 6.  Non-invasive investigation of myocardial energetics in cardiac disease using 31P magnetic resonance spectroscopy.

Authors:  Mark A Peterzan; Andrew J M Lewis; Stefan Neubauer; Oliver J Rider
Journal:  Cardiovasc Diagn Ther       Date:  2020-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.